Ascendis
1 products tracked · names used in filings: Ascendis
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 27 Feb 2026🇺🇸 FDA approval
FDA approves Yuviwel (navepegritide), a new medicine
Ascendis; NDA219164; New molecular entity, Priority review; powder · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Yuviwel navepegritide | Approved | 2026-02-27 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.